ArticleRevista panamericana de salud publica = Pan American journal of public health2026
Strengthening access to antihypertensive medicines through HEARTS in the Americas: the Grenada experience.
Article in Revista panamericana de salud publica = Pan American journal of public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To describe how Grenada leveraged the HEARTS in the Americas standardized clinical pathway to strengthen procurement of a single-pill fixed-dose antihypertensive and align prescribing and procurement across public and private sectors. Methods: Grenada adopted a national hypertension clinical pathway specifying a single-pill fixed-dose combination of telmisartan/amlodipine with chlorthalidone as preferred therapy. Implementation strategies included integration of pathway medicines into the essential medicines list and procurement systems; engagement of clinical and procurement leadership; dissemination to private providers; and engagement with private pharmacies. A descriptive analysis was conducted using predefined indicators aligned with adoption, feasibility, acceptability, and public-private alignment using survey data, program documents, procurement records, and routine reports. Results: Integration of the standardized regimen into procurement processes supported availability of telmisartan/amlodipine and chlorthalidone in public primary care facilities, although supply gaps persisted. Adoption of a single national pathway supported standardized prescribing, forecasting, and centralized procurement. Dissemination to private clinicians and pharmacies contributed to uptake in the private sector, with pharmacies independently procuring pathway medicines, supporting continuity of care across sectors, although alignment remained incomplete. Facilitators included early stakeholder engagement, alignment between clinical and procurement leadership, and regimen simplification. Limitations included data system gaps and supply chain constraints. Conclusions: A standardized clinical pathway can strengthen procurement and promote public-private alignment in hypertension care. Addressing supply chain constraints remains essential for sustained access and continuity of treatment, with lessons applicable to other small island developing states implementing HEARTS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.